Despite the potency with which dendritic cells (DCs) are able to utilize the exogenous MHC I antigen cross-presentation pathway to cross-present antigen for the activation of killer T cells in model systems, concern about defects in immune function in cancer patients has led to uncertainty regarding whether immune cells derived from patients can effectively be used to generate tumor vaccines. We have undertaken a careful analysis of the potency of using DCs obtained from prostate cancer patients to cross-present antigen derived from human prostate tumor cells for the activation of antigen-specific T cells. Such DCs can be matured ex vivo into functionally active cells and are capable of cross-presenting influenza antigen derived from internalized apoptotic prostate tumor cells. Importantly, we demonstrate effective stimulation of both CD4 þ and CD8 þ T cells, as evident by production of IFN-c, and the ability of CD8 þ T cells to differentiate into effector CTLs. These results, defining conditions in which prostate cancer patient DCs can efficiently utilize the cross-presentation pathway and in which apoptotic tumor can serve as a source of antigen for DCs to activate T cells, demonstrate that this system warrants clinical study as a potential immunotherapy.
Introduction
It has been proposed that apoptotic tumor cells may serve as a source of antigen for presentation by the immune system for the activation of effective human tumor immunity. 1 Apoptotic cells are able to deliver antigen to dendritic cells (DCs), where peptide epitopes derived from these antigens are delivered to both MHC I and MHC II molecules. [2] [3] [4] [5] Loading of MHC I with antigen derived from exogenous material offers a physiologic mechanism for the in vivo phenomenon referred to as 'cross-presentation. ' 6 Several studies have shown that the cross-presentation of antigen derived from dying tumor cells and virally infected cells can efficiently load MHC I and MHC II molecules of monocyte derived DCs, which can in turn activate tumor-and virus-specific CD8 þ and CD4 þ T cells. 7, 8 To achieve activation of effector CTLs via this pathway, the DC must receive both a maturation stimulus as well as a signal from a CD4 helper T cell (eg CD40L). 9 Delivery of antigen via cross-presentation as a strategy for immunization confers the advantage of allowing DCs to present wide arrays of antigen (both known and unknown) expressed by tumor cells, potentially activating a diverse repertoire of tumor-specific CTLs. Additionally, this approach bypasses the need to determine specific MHC I epitopes, as the DCs do this naturally during the processing of exogenous antigen. Accordingly, DCs cross-presenting apoptotic tumor cells present antigen independent of the patient's HLA haplotype, potentially loading all of the different HLA alleles present on the DC. Moreover, antigen loading via this pathway has been shown to be 3000-10 000 times more efficient than in vitro surface loading DCs with peptide, and up to 50 000 times more efficient than whole protein injected intravenously. 5, 10 Finally, by delivering antigen derived from apoptotic tumor cells to autologous DCs, it may be possible to induce effective CD4 þ helper T cells thus supporting the survival of CD8 þ memory T cells. 9 We have applied this approach toward the establishment of a tumor vaccine protocol for prostate cancer patients. Prostate cancer is among the top three cancers afflicting American men, with a prevalence of 8 million, 11 and an expected incidence of nearly 189 000 and with approximately 30 200 deaths in 2002 according to the American Cancer Society. While chemotherapy, radiation treatment, and hormonal ablation kill a proportion of tumor cells, the cells that survive do so in a growtharrested state 12 and it is these cells, resistant to conventional therapy, that a successful tumor-cell vaccine may target. Prostate cancer patients offer several advantages as candidates for new tumor immunotherapies. Patients with rising PSA levels who have failed conventional therapy are at high risk for metastatic disease and death within 5 years. 13 Furthermore, as chemotherapy has no proven benefit in this patient cohort, these patients offer the chance to test experimental immunotherapy protocols in chemo-naïve individuals, an important issue given the toxic effects of chemotherapy on the immune system.
There is a substantial body of literature suggesting that DCs prepared ex vivo from healthy volunteers, and in some instances from cancer pateints, have the functional attributes (capable of priming de novo T cell responses) of DCs in vivo (see Banchereau and Steinman 14 and Bhardwaj 15 for reviews). The specific question of the competence of DCs obtained from prostate cancer patients has been raised in previous studies, yet no systematic screening of DC function in this patient cohort has been reported. Some data have suggested defects in the immune state in prostate cancer patients, and thus raised the question of whether they would be reasonable candidates for immune based anticancer vaccination. 16 In one prostate cancer clinical study, poor functionality of patient DCs has been offered as an explanation for lack of responsiveness to a DC vaccination protocol. 17 Here, we report that prostate cancer patient DCs are capable of generating MHC-peptide complexes from antigen cross-presented from internalized apoptotic prostate cancer cells. Specifically, we demonstrate the ability to reproducibly culture functional DCs derived from prostate cancer patients, monitor the ability of prostate cancer patient DCs to phagocytose and crosspresent antigen derived from apoptotic prostate tumor cells, and utilize these DCs to stimulate antigen-specific autologous CD4
þ and CD8 þ T cell responses.
Methods

Isolation and preparation of cells
Peripheral blood mononuclear cells (PBMCs), DCs, and T cells were prepared as previously described. 18 Briefly, peripheral blood was obtained from normal donors in heparinized syringes and PBMCs were isolated by sedimentation over Ficoll-Hypaque (Amersham Pharmacia Biotech, Piscataway, NJ, USA). T-cell-enriched and Tcell-depleted fractions were prepared by rosetting with neuraminidase-treated sheep red blood cells. Immature dendritic cells (DCs) were prepared from the T-celldepleted fraction by culturing cells in the presence of granulocyte and macrophage colony-stimulating factor (GM-CSF, Immunex, Seattle, WA, USA) and interleukin-4 (IL-4, R&D Systems, Minneapolis, MN, USA) for 6 days. Volumes of 1000 U/ml of GM-CSF and 500-1000 U/ml of IL-4 were added to the cultures on days 0, 2 and 4. To generate mature DCs, the cultures were transferred to fresh wells on day 6 and a mixture of 50 ng/ml tumor necrosis factor-alpha (TNF-a, Alexis Biochemicals, San Diego, CA, USA) and 0. 
and CD8
þ T cells were further purified to 499% purity by positive selection using the MACS column purification system (Miltenyi Biotech, Auburn, CA, USA).
Induction of apoptotic death
The mouse lymphoma cell line EL4 (ATCC #TIB-39), the human prostate carcinoma cell line LNCaP (ATCC #CRL-1740) and the human prostate carcinoma cell line PC-3 (ATCC #CRL-1435) were used as a source of apoptotic cells as they can all be efficiently infected with influenza virus. The LNCaP, EL4 and PC-3 cells were infected with influenza, incubated for 5 h to allow expression of influenza proteins and washed out of serum containing media. Apoptosis was triggered using a UV-B lamp (Derma Control, Inc., Old Forge, PA, USA) calibrated to provide 120 mJ/cm 2 /s. Infected and uninfected LNCaP, EL4 and PC-3 cells were harvested after UV-B irradiation at various time points and incubated with carboxyfluorescein-labeled fluoromethyl ketone (FMK)-peptide inhibitors of caspases for 1 h at 371C (CaspaTag kit, Intergen, Purchase, NY, USA). Cells were then washed three times in PBS. A volume of 5 mg/ml propidium iodide (PI) was added and samples were acquired and analyzed on a FACS Calibur flow cytometry machine.
In vitro and in vivo confirmation of replication incompetence of apoptotic cells LNCaP and PC-3 cells were exposed to 120 mJ/cm 2 UV-B and incubated at 371C for 10-12 h to allow for the initiation of apoptotic death. A total of 10 6 UV-Birradiated or live cells were pulsed with 4 mCi/ml 3 Hthymidine and incubated at 371C for 12-16 h. Cells were assayed for beta emission and counts per minute (cpm) 
Detection of antigen-specific T cells
ELISPOT assay for IFN-g release Immature DCs, apoptotic cells and a DC maturation stimulus (TNF-a and PGE-2) were incubated together for 36 h to allow for phagocytosis of the apoptotic EL4 and PC-3 cells, antigen processing and DC maturation. The DCs were collected, counted and plated in wells containing purified T-cell populations precoated with 5 mg/ml of a primary anti-IFN-g mAb (clone Mab 1-DIK) (Mabtech, Sweden). In all experiments, 2 Â 105 T cells were added to 6.6 Â 10 3 DCs to give a 30 : 1 T cell : DC ratio. CD40L was added to the CD8 þ T cell and DC cocultures to bypass the requirement for CD4 help. 9 The cultures were incubated in the plates for 40-44 h at 371C. At that time, the ELISPOT plate was developed. Briefly, cells were washed out using mild detergent and the plates were incubated with 1 mg/ml biotin-conjugated IFN-g mAb (clone Mab 7-B6-1) (Mabtech, Sweden). Wells were next stained using the Vectastain Elite Kit as per the manufacturer's instructions (Vector Laboratories, Burlingame, CA, USA Cr releaseÀspontaneous release)/(total releaseÀ spontaneous release) Â 100%). Specific lysis was determined by subtracting the percent lysis of unpulsed T2 cells. Influenza-infected DCs or matrix peptide pulsed DCs served as controls in all experiments in order to measure the donor's maximal CTL responsiveness to influenza. Background lysis ranged from 0 to 10% for the unpulsed T2 cells.
Results
Infection and generation of apoptotic prostate tumor cells
We tested the ability of the prostate cancer cell lines, LNCaP and PC-3, to package and deliver shared antigens to DCs as measured by effective apoptosis, phagocytosis and subsequent cross-presentation by dendritic cells. In order to develop an effective model system, which would allow us to track antigen cross-presentation and T-cell activation, we infected LNCaP and PC-3 cells with influenza virus and assessed their expression of the influenza M1 (matrix) antigen. FACS analysis revealed that 6 h after infection the M1 antigen could be detected in both LNCaP and PC-3 cells (Figure 1a) .
We next confirmed that apoptotic death could be induced in prostate cancer cells following UV-B irradiation. Upon receiving a death stimulus, cells activate caspases and undergo apoptotic death as evident by single positive staining with CaspaTag, which detects activated caspase molecules (Intergen). PI, a fluorescent marker excluded by cells with an intact plasma membrane, intercalates into the DNA of necrotic cells that have lost membrane integrity. UV-B irradiation of 120 mJ/cm 2 was able to successfully induce apoptosis in LNCaP and PC-3 cells within 24-48 h (Figure 1b) . Notably, secondary necrosis, as evident by PI labeling, did not occur under these conditions ( Figure 1b ) until after 44 h.
A proportion of UV-B-irradiated cells examined at 48 h were neither CaspaTag nor PI positive. For apoptotic tumor cells to be considered as a source of antigen in clinical trials, it would be important to confirm that UV-B-irradiation results in efficient cell killing. We first assessed whether UV-B irradiated cells were able to replicate in vitro by measuring 3 H-thymidine incorporation at 48 h. (Figure 1e ). To demonstrate that the method of uptake was indeed phagocytosis, cocultures were also incubated at 41C and in EDTA, conditions which are both known to inhibit phagocytosis ( Figure 1e ). While there was an apparent delay in induction of early apoptotic death, phagocytosis was still effective suggesting that in vitro assays for measuring apoptotic death may be less efficient than a DC's ability to recognize early markers for programmed cell death. 21 Apoptotic prostate tumor cells provide antigen for dendritic cell cross-presentation
We next examined whether apoptotic tumor cells could be processed by DCs to stimulate functional influenza-specific T cells as effectively as previously described cell lines. For these purposes, we developed an ELISPOT assay to examine antigen-specific IFN-T-cell responses. In these experiments, we compared the ability of apoptotic LNCaP and PC-3 cells to serve as a source of antigen as compared to apoptotic EL4 cells, a mouse thymoma cell line used as a positive control. 9 As an additional control, DCs were directly infected with the influenza virus, allowing for antigen processing and presentation via the classical MHC I endogenous pathway. Apoptotic LNCaP and PC-3 were both able to transfer antigen to DCs for the stimulation of influenza specific T cells, and did so as effectively as EL4 cells (Figure 2 ). We conclude that the observed T-cell responses were influenza antigenspecific and not allogeneic responses to LNCaP or PC-3, as no significant T-cell stimulation was detected in cultures containing DCs presenting apoptotic tumor cells alone. Phagocytosis was measured by FACS analysis and green DCs that acquired red apoptotic LNCaP or PC-3 were scored as positive. To confirm that the method of uptake was indeed phagocytosis, cocultures were also incubated at 41C (diamond) and in EDTA (star), which are both known to inhibit phagocytosis.
Antigen
Prostate cancer patient DCs are functional and immunologically competent
It has been suggested that prostate cancer patients may be immunocompromised. 16 To explore this issue, we examined whether it was possible to differentiate and mature dendritic cells from the peripheral blood monocyte precursors of stage IV prostate cancer patients. These studies were performed using autologous serum, allowing us to assess whether patient serum itself might harbor inhibitory factors. Peripheral blood from six stage IV prostate cancer patients (Table 1) was processed as described in Methods. 18 Briefly, peripheral blood monocytes were obtained by peripheral blood draw or leukapheresis, grown for 6 days in the presence of GM-CSF and IL-4, and matured in the presence of PGE-2 and TNF-a. Data from four representative patients are shown (Figure 3a) . In all six patients examined, FACS analyses of DCs revealed that they expressed CD86, CD83, and high levels of HLA-DR, and that they lacked expression of CD14, all of which were consistent with the phenotype of mature DCs. In addition, these cells exhibited a stellate morphology characteristic of mature DCs (data not shown).
We next evaluated whether prostate cancer patient DCs could stimulate allogeneic T cells in a functional assay. The allogeneic mixed-lymphocyte reaction (allo-MLR) assay provides a means for assessing the viability, maturity and function of dendritic cells. By measuring uptake of 3 H-thymidine, it was possible to compare the ability of patient and normal volunteer DCs to stimulate T-cell proliferation. The results of these assays demonstrated that prostate cancer patient DCs were nearly as potent as normal volunteer DCs in their ability to present and stimulate T-cell division ( Figure 3b) ; similar results were seen in six of six prostate cancer patients assayed (data not shown). A small difference in the stimulatory capacity of DCs observed (Figure 3b ) may relate to differences in the population of precursor cells that were harvested (normal control cells were obtained from buffy coats, while prostate patient cells were obtained by leukapheresis). Taken together, these data confirm that functionally mature DCs can be generated from the peripheral blood of prostate cancer patients.
Prostate cancer patient DCs cross-present apoptotic antigen as efficiently as normal control DCs
To further examine the functionality of prostate cancer patient DCs, we assessed their ability to cross-present antigen derived from prostate cancer cells for the activation of syngeneic T cells. The ELISPOT assay was employed to measure antigen-specific IFN-g responses of purified CD4 þ and CD8 þ T cells in order to evaluate Antigen cross-presentation and prostate cancer DE Orange et al whether antigen was presented on both MHC class I and MHC class II molecules. DCs directly infected with the influenza virus (expressing MHC I peptide via the classical or endogenous pathway) and DCs that had phagocytosed infected apoptotic EL4 cells (presenting antigen via the cross-presentation or exogenous pathway) served as positive controls, while uninfected DCs and DCs that had phagocytosed uninfected cells served as negative controls. CD8 þ T cells were incubated with cross-presenting DCs in the presence of agonistic CD40 antibody to substitute for CD4 T cell help. 9 When apoptotic LNCaP or PC-3 cells infected with influenza were cross-presented by DCs, antigen specific CD8 þ and CD4 þ T cell responses were elicited (Figure 4a ). Similar results were obtained in six out of six patients (Table 2) . We conclude that prostate cancer patient DCs effectively cross-present apoptotic prostate cancer material for the generation of both CD4 þ and CD8 þ T cell responses.
Prostate cancer patient DCs can cross-present antigen for the generation of antigen-specific CTLs
Several patients studied were HLA-A2.1 positive, allowing us to evaluate the induction of HLA-restricted effector CTLs by cytotoxicity assays. DCs obtained from HLA-A2.1 þ prostate cancer patients were cocultured with apoptotic influenza-infected LNCaP and PC-3 cells and these charged DCs were used to stimulate CD8 þ T cells in the presence of agonistic anti-CD40 antibody. Influenza-infected DCs served as a positive control for classical MHC I endogenous presentation, while uninfected DCs and DCs that had phagocytosed uninfected cells served as respective negative controls. Cytotoxic Tcell activity was assessed by measuring 51 Cr release from T2 cells pulsed with matrix peptide. CD8 þ T cells stimulated by DCs cross-presenting influenza antigen from apoptotic prostate cancer cells were able to lyse T2 targets that had been pulsed with the HLA-restricted influenza matrix peptide in two out of three patients, but not able to lyse control T2 cells ( Figure 5 , Table 2 ). In controls in which PSMA peptides were used, no significant lysis over background was seen (data not shown). These data indicate that prostate cancer patient DCs effectively cross-present influenza antigen derived from apoptotic prostate tumor cells for the generation of antigen-specific cytotoxic T cells.
Discussion
In previous studies, we have demonstrated that DCs obtained from normal volunteers or patients with paraneoplastic neurologic disorders are able to crosspresent antigen for the activation of antigen-specific Tcell responses. [2] [3] [4] In the current study, we have extended this work to show that DCs obtained from a general population of prostate cancer patients are able to process antigen derived from apoptotic prostate tumor cell lines for the activation of antigen-specific CD4 þ and CD8 þ T cell responses. These data provide a foundation for considering the use of apoptotic tumor cells in vaccination strategies to stimulate tumor immune responses in cancer patients.
Previous studies assessing the effectiveness of immunotherapy in prostate cancer, generally using defined prostate tumor peptides as a source of antigen, have met with mixed success. 17, 22, 23 The current study provides the first effort to focus specifically on the ability of apoptotic prostate tumor cells to cross-present tumor antigens to prostate cancer patients autologous DCs. We have identified two prostate cancer cell lines, LNCaP and PC-3, that can be used to cross present antigen. These cells were infected with influenza virus (Figure 1a) , establishing an internal positive control to monitor the efficacy of antigen cross-presentation from prostate tumor cells.
We have demonstrated that LNCaP and PC-3 can be rendered apoptotic through UV-B irradiation and can be effectively phagocytosed by functional immature dendritic cells (Figure 1b-d) . This is significant in light of a number of reports in which necrotic tumor lysates have been compared with apoptotic tumor cells in preclinical and clinical studies. In these studies, tumor lysates have been prepared using various protocols (such as freeze-thaw), generating a population of poorly defined necrotic and possibly some apoptotic cells, and in some clinical studies, limited responses post vaccine to tumor lystaes have been seen in some (eg 3/10 samples of patient peripheral blood lymphocytes; 24 see Bhardwaj 15 for a review). Many, but not all, pre-clinical Several explanations may underlie the limited responses seen in tumor lysate-based vaccinations, and the potentially improved response to apoptotic tumor cells. The efficacy of DC cross-presentation to T cells depends critically on the state of the antigen to which the DC is exposed. Apoptotic cells are a natural and potent source of antigen. Apoptotic cells are phagocytosed by avb5 and CD36 þ receptors on DCs, 20 and then processed and presented to T cells on both MHC class I and II molecules. 2, 3, 5, 29 The potency of DC cross-presentation of apoptotic cells to T cells depends critically on the ability to present antigen to both CD4 þ and CD8 þ T cells. In the absence of CD4 þ help, DCs cross-presenting antigen tolerize rather than activate CD8 þ T cells. 9, 30 Therefore, careful attention to the type of cell death induced in tumor cell vaccination, as well as the ability of antigen to activate both CD4 þ and CD8 þ T cells, may be of importance in generating reproducible and potent results.
We find that DCs obtained from six out of six prostate cancer patients can be differentiated from peripheral blood monocytes to have a mature surface phenotype as assessed by FACS, and are fully functional, as assessed by allo-MLR (Figure 3) . Considering the severity of disease and the toxicity to the immune system of treatments administered in cancer patients, it has been uncertain whether cancer patient DCs are capable of stimulating T-cell mediated immunity. In a study where PSMA peptide-pulsed DCs were used to stimulate antigen-specific T cells in prostate cancer patients, only two of 82 men showed responses. 31 It has been suggested that the low frequency of immune responses might have resulted in part from poor DC function. 17 In other studies, only 25-35% of advanced stage prostate cancer patients were considered fully immunocompetent, as assessed by DTH responses to diphtheria/tetanus, streptokinase and mumps, and 33% of patients were found to be completely anergic. 14, 23, 32 While multiple aspects of cell-mediated immune responses may be defective in prostate cancer patients, these observations underscore the significance of our ability to document the ability to obtain functional DCs from six out of six prostate cancer patients.
We also demonstrate that DCs derived from six out of six prostate cancer patients can phagocytose apoptotic LNCaP and PC-3 cells for the generation of both MHC I and MHC II/peptide complexes and the activation of CD4 þ and CD8 þ T cells, as assessed by ELISPOT assay (Figure 4) . Moreover, these DCs are able to stimulate CD8 þ memory T cells into antigen-specific effector CTLs capable of lysing peptide-loaded target cells ( Figure 5 ). We demonstrate here that DCs derived from prostate cancer patients are indeed immunologically competent and are able to activate, and not tolerize, functional T-cell responses in six out of six prostate cancer patients. We conclude that DCs cross-presenting apoptotic tumor cells may form the basis of an effective immune-based clinical vaccination strategy in prostate cancer patients. Antigen cross-presentation and prostate cancer DE Orange et al responses. 33, 34 Numerous ongoing trials are underway in melanoma, myeloma and other cancers, in which patients are vaccinated with DCs that have been pulsed with the HLA-A2.1 epitopes of tumor-associated antigens, including MAGE-3, Melan A/MART-1 for melanoma, and, in prostate cancer, PSMA-1/2.
14,33,35 While peptide-pulsed DCs have shown some clinical response in tumor immunotherapy trials, they entail a number of inherent disadvantages addressed by our results. DCs pulsed with peptides from antigens that are not critical for tumor growth may allow tumors to evade lysis by activated CD8 þ T cells by downregulating expression of the targeted tumor antigen or presentation of the relevant epitope. Such escape has been documented in melanoma patients treated with MAGE peptide-pulsed DCs, who have shown recurrence of disease with MAGE-negative tumors. 36, 37 Clearly, an attractive feature of our strategy to cross-presenting apoptotic tumor to DCs is its potential to immunize against a broad range of tumor antigens.
Although the use of peptides derived from multiple tumor antigens may help address the problem of tumor escape, it has also proven difficult to identify large numbers of useful tumor antigens. In addition, the use of peptide antigens is hindered by the high degree of MHC polymorphism. Indeed, peptide-DC vaccines are restricted to one HLA haplotype (generally HLA A2.1). This restricts the number of patients eligible for such vaccines, and underutilizes the potential breadth of the immune response to any one antigen. This is particularly in issue in prostate cancer, where African Americans are over-represented, but in whom there is a o20% incidence of the HLA A2.1 allele. 38 We have shown that we are able to cross-present apoptotic material derived from whole prostate tumor cells to DCs for the activation of autologous T cells. This offers the possibility of activating a broad spectrum of potentially tumor reactive T cells, allowing immunization without prior knowledge of specific tumor antigens, yet while presenting any one antigen on multiple HLA molecules.
An essential feature of studies utilizing DC-based immunotherapy will be to monitor that antigen crosspresentation indeed results in effective boosting of antigen-specific T cells. We have demonstrated that prostate tumor cells expressing model antigens, may effectively be utilized to provide such a positive control. The ability to follow responses to such a control antigen will allow for accurate conclusions regarding safety and efficacy, thereby providing an important addition to current tumor immunotherapy studies.
Another difficulty with the use of peptide vaccines is that HLA class I-restricted peptides are able to activate antigen-specific CD8 þ T cells, but not CD4 þ T cells. This is significant, as CD4 þ T cells are important for the activation and maintenance of CD8 þ effector memory cells. 9, 30, 39, 40 An observation of significant clinical importance to DC immunotherapy is that CD8 þ T cells become tolerized rather than activated in the absence of such CD4
þ T cell help. 9 We show here that apoptotic Antigen cross-presentation and prostate cancer DE Orange et al prostate tumor cells effectively cross-present antigen to activate both antigen-specific CD4 þ and CD8 þ T cells. These observations, taken together with our current results, suggest that the cross-presentation pathway outlined in this paper may prove to be of particular clinical value.
